Century Therapeutics Stock Performance
| IPSC Stock | USD 0.60 0.0001 0.02% |
On a scale of 0 to 100, Century Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 0.86, which signifies possible diversification benefits within a given portfolio. Century Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Century Therapeutics is expected to follow. Please check Century Therapeutics' sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Century Therapeutics' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Century Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Century Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Century Therapeutics, Inc. May Report Negative Earnings Know the Trend Ahead of Q1 Release | 05/01/2025 |
2 | Disposition of 295 shares by Carr Douglas of Century Therapeutics at 0.55 subject to Rule 16b-3 | 05/05/2025 |
3 | Verrica Pharmaceuticals Inc. Reports Q1 Loss, Tops Revenue Estimates | 05/13/2025 |
4 | Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 05/15/2025 |
5 | What is Chardan Capitals Estimate for IPSC FY2025 Earnings | 05/22/2025 |
6 | HC Wainwright Analysts Increase Earnings Estimates for IPSC | 05/29/2025 |
7 | Disposition of 526 shares by Gregory Russotti of Century Therapeutics at 0.622 subject to Rule 16b-3 | 06/09/2025 |
8 | Disposition of 552 shares by Adrienne Farid of Century Therapeutics at 0.622 subject to Rule 16b-3 | 06/11/2025 |
9 | Acquisition by Walbert Timothy P of 44000 shares of Century Therapeutics at 0.6 subject to Rule 16b-3 | 06/12/2025 |
10 | uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development | 06/16/2025 |
11 | Century Therapeutics Is Attractively Priced Despite Fast-paced Momentum | 06/25/2025 |
12 | Century Therapeutics Files for 200M Mixed Securities Offering IPSC Stock News | 07/10/2025 |
| Begin Period Cash Flow | 49.3 M |
Century Therapeutics Relative Risk vs. Return Landscape
If you would invest 50.00 in Century Therapeutics on April 15, 2025 and sell it today you would earn a total of 9.99 from holding Century Therapeutics or generate 19.98% return on investment over 90 days. Century Therapeutics is currently generating 0.379% in daily expected returns and assumes 4.1964% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Century, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Century Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Century Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Century Therapeutics, and traders can use it to determine the average amount a Century Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0903
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IPSC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.2 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Century Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Century Therapeutics by adding it to a well-diversified portfolio.
Century Therapeutics Fundamentals Growth
Century Stock prices reflect investors' perceptions of the future prospects and financial health of Century Therapeutics, and Century Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Century Stock performance.
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.0559 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.68 % | ||||
| Current Valuation | (60.72 M) | ||||
| Shares Outstanding | 86.16 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 0.22 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 6.59 M | ||||
| Gross Profit | 4.5 M | ||||
| EBITDA | (111.47 M) | ||||
| Net Income | (126.57 M) | ||||
| Cash And Equivalents | 378.76 M | ||||
| Cash Per Share | 6.43 X | ||||
| Total Debt | 53.83 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.79 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (110.14 M) | ||||
| Earnings Per Share | (0.27) X | ||||
| Market Capitalization | 51.72 M | ||||
| Total Asset | 353.22 M | ||||
| Retained Earnings | (782.34 M) | ||||
| Working Capital | 64.27 M | ||||
About Century Therapeutics Performance
By analyzing Century Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Century Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Century Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Century Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (22.90) | (21.76) | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.78) | (0.75) |
Things to note about Century Therapeutics performance evaluation
Checking the ongoing alerts about Century Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Century Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Century Therapeutics has some characteristics of a very speculative penny stock | |
| Century Therapeutics had very high historical volatility over the last 90 days | |
| Century Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with profit before overhead, payroll, taxes, and interest of 4.5 M. | |
| Century Therapeutics currently holds about 378.76 M in cash with (110.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Century Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Century Therapeutics Files for 200M Mixed Securities Offering IPSC Stock News |
- Analyzing Century Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Century Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Century Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Century Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Century Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Century Therapeutics' stock. These opinions can provide insight into Century Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |